ARTICLE | Finance

Safety first

Safety data enabled antibiotics play VenatoRx to attract institutional investors

July 29, 2017 1:23 AM UTC

Phase I safety data for VNRX-5133 enabled VenatoRx Pharmaceuticals Inc. to bring its first institutional investors on board for a $42 million series B round.

Versant Ventures led the tranched round on July 25, joined by Abingworth and Foresite Capital. Details of the tranches are undisclosed...

BCIQ Company Profiles

Venatorx Pharmaceuticals Inc.

BCIQ Target Profiles

Beta lactamase (LACTB)